Clareo Health | ARTDeCo Study: A Study of RO4995819 in Patients With Major Depressive Disorder And Inadequate Response to Ongoing Antidepressant Treatment
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Adult patients, 18-65 years of age
Major depression disorder without psychotic features
Inadequate response to current, ongoing antidepressant treatment as defined by protocol
Having at least one but no more than 2 antidepressant treatment trial failures
Body mass index (BMI) 18.0-35.0 kg/m2 inclusive
You may not be if
Patient currently receives treatment with a combination of 3 or more antidepressants
Significant ongoing use of high doses of barbiturates, benzodiazepines or other anxiolytic drugs
Patient previously received RO4995819
Patient participated in an investigational drug or device trial within 6 months of screening
History of non-response to, or current use of non-pharmacological treatment including Electroconvulsive Therapy (ECT), Vagus Nerve Stimulation (VNS), or Repetitive Transcranial Magnetic Stimulation (RTMS)
